OSUMERLI
LIVE

Serial Number

79345963

Owner

Sandoz AG

Filing Date

May 24, 2022

Add to watchlist:

No watchlists yet
View on USPTO

OSUMERLI Trademark

Serial Number: 79345963 • Registration: 6976472

OSUMERLI is a trademark filed by Sandoz AG on May 24, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Sandoz AG (9 trademarks)

Viaduktstrasse 3

Entity Type: 03

Novartis AG (17 trademarks)

CH-4002 Basel

Entity Type: 03

Trademark Details

Filing Date

May 24, 2022

Registration Date

February 14, 2023

Published for Opposition

November 29, 2022

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Sep 3, 2026 NREP
CHANGE OF OWNER RECEIVED FROM IB
Jan 19, 2024 CHLD
NOTIFICATION PROCESSED BY IB
Apr 23, 2023 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
Apr 3, 2023 FICS
FINAL DISPOSITION PROCESSED
Apr 3, 2023 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Mar 16, 2023 GPAR
REGISTERED-PRINCIPAL REGISTER
Feb 14, 2023 R.PR
NOTIFICATION PROCESSED BY IB
Dec 13, 2022 GPNX
PUBLISHED FOR OPPOSITION
Nov 29, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 23, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 23, 2022 OP2R
NOTICE OF PUBLICATION
Nov 9, 2022 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 24, 2022 CNSA
ASSIGNED TO EXAMINER
Oct 17, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 5, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 1, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 29, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 28, 2022 REPR